ALT
Altimmune, Inc. (NASDAQ)
Healthcare — Biotechnology
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Buy
1.5 / 5
10 analysts
$2.81
$-0.01 (-0.35%)
Target:
$15.45
(449.8%)
Sign in to add ALT to a watchlist or set price alerts.
Price History
Fundamentals
| Market Cap | $623.29M |
| P/E Ratio (TTM) | - |
| Forward P/E | -3.73 |
| EPS (TTM) | $-0.92 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | - |
| Recommendation | Buy 1.5 |
| Analyst Target | $15.45 |
| Analysts | 10 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 80.6 |
| Beta | 0.23 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | - |
| 52-Week Low | - |
| 50-Day Avg | - |
| 200-Day Avg | - |
| Avg Volume | $4.43M |
| Volume | $2.24M |
Performance Analysis
NEUTRALALT presents a mixed picture with both positive and negative indicators.
-
RSI at 80.6 indicates overbought conditions — a pullback may be due.
+
Wall Street consensus is "Buy" from 10 analysts.
+
Average analyst target of $15.45 implies 449.8% upside.
Recent News
Loading news...
Last updated: Jul 01, 2026 15:01 UTC
Back to Screener Export Report